Salvatore Perrone

Hematologist.

[Kohei Hasegawa @kbot13533737]

Infectious Risks Associated with Biologic Therapies in Autoimmune, Rheumatologic and Dermatologic Diseases: A Narrative Review - Microorganisms (2026)

https://t.co/QjUYdOTyii

[Salvatore Perrone @Salva_Perrone]

@LymphomaAction @Lymphoma_Papers

[Salvatore Perrone @Salva_Perrone]

Does RCT efficacy for Pola-R-CHP hold up in everyday practice? 🏥🔬In our systematic review & meta-analysis in @BloodCancerJnl 3,472 patients), we confirmed that real-world outcomes match—and sometimes exceed—RCT results for DLBCL:https://t.co/IEnfTA0sAN #Lymphoma #HemOnc #DLBCL

[Salvatore Perrone @Salva_Perrone]

@OncoAlert

[Salvatore Perrone @Salva_Perrone]

New multicenter real-world study published in Annals of Hematology 📊 How is the infection risk after #Rituximab in autoimmune hematological disorders? Research on 285 patients across 7 Italian centers shows it is comparable to NHL #Anemia #ITP #lymphoma https://t.co/pIbbzv6UAf

[Guilherme Perini, MD @GuiperiniMD]

There are 2 types of DLBCL who relapse in CNS

MCD
MYC-R

Thats why all trials will be negative.

What I would do?
IBTK for all MCD
IT + HDMTX for MYC-R
https://t.co/puQOx4mTk8

[Salvatore Perrone @Salva_Perrone]

Many thanks for this briliant Editorial to Brandon Aubrey and Amir Fathi

[ACS Journal Cancer @JournalCancer]

🔬 In a new editorial, Dr. Brandon Aubrey and CANCER Editorial Board Member Dr. Amir Fathi discuss the Perrone et al. meta-analysis on HMA + venetoclax in younger adults with AML.

Editorial: https://t.co/vssfhnoKda

Study: https://t.co/SgOM6fFaXu

@OncoAlert @MassGenBrigham

[Salvatore Perrone @Salva_Perrone]

📢 First report of a KRAS mutation in T-prolymphocytic leukemia (T-PLL).

This discovery may point toward new therapeutic targets for this aggressive and rare T-cell disorder.

Check out the full report in @SpringerNature: https://t.co/yWFVRwQDQn

#BloodCancer #PrecisionMedicine

[ACS Journal Cancer @JournalCancer]

New findings support hypomethylating agents/venetoclax as an effective induction strategy in selected younger patients with #AML and provide a rationale for prospective randomized trials comparing this approach with IC-based regimens.

https://t.co/SgOM6fFaXu

@OncoAlert #LeuSM

[Salvatore Perrone @Salva_Perrone]

Our latest meta-analysis just accepted in @Cancer_Journal! 🚀

Is intensive chemotherapy still the gold standard for younger AML, or is the paradigm shifting to HMA+Venetoclax? 🩸

We analyzed data. Here’s what we found:
https://t.co/q5jSBJS3zq
#AML #Leukemia #HemOnc #MedTwitter

[Salvatore Perrone @Salva_Perrone]

@AML_Hub Thanks for posting it

[AML Hub @AML_Hub]

New publication 📝 Real-world data, published in Annals of Hematology, show median OS was 21 months in patients with secondary #AML receiving IDAC consolidation after CPX‑351 induction. Adverse-risk disease and pre‑IDAC MRD positivity were negative prognostic factors.

Learn more: https://t.co/QtJEVrYqWR

#AMLsm #MedNews #MedEd @Salva_Perrone

[Salvatore Perrone @Salva_Perrone]

Coming soon…

#aml #leukemia

[Salvatore Perrone @Salva_Perrone]

Dealing with CNS involvement in #AML is always a hurdle. When #FLT3-ITD mutations are involved, the complexity grows. 🧠🩸

Check out our report on relapsing meningeal AML published in Chemotherapy.

📖 Full article: https://t.co/DCFZsv8JGp

#HemOnc #MedEd #AMLsm #BloodCancer

[Salvatore Perrone @Salva_Perrone]

Is IDAC an option for secondary AML consolidation? This Italian multicenter study explores using intermediate-dose ARA-C after CPX-351.

Results? It's a safe, effective, and lower-cost strategy.

Check it out: https://t.co/nrMtx02HAM #AML #Hematology #Oncology #MedicalStudy

[Benlazar S M A @smbenlazar]

How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to Know https://t.co/PH1XNpp7S2 #mdpijcm via @JCM_MDPI #leusm

[Salvatore Perrone @Salva_Perrone]

Kate, thanks for giving the first place to our educational paper on Ngs!! 🏆

[Kate Sears @OpenMedKate]

Hi friends, it's #AcuteMyeloidLeukemia Thursday! Here are Top Posts of the Week 🧵

1/ @smbenlazar on NGS reports for AML:
https://t.co/jprckXQts4

[Salvatore Perrone @Salva_Perrone]

@smbenlazar @JCM_MDPI Thanks 🙏

[JCM MDPI @JCM_MDPI]

#mdpijcm
📢Explore the 357 new articles in Volume 14, Issue 24
👉https://t.co/yxqIlBAawz
#IssueCover
How to Read a Next-Generation Sequencing Report for #AML and #MDS? What Hematologists Need to Know
🎯https://t.co/Y5dcJyovjw
👥@Salva_Perrone
@MediPharma_MDPI

[Salvatore Perrone @Salva_Perrone]

📢 Just Published in @Haematologica

We are excited to share our latest meta-analysis on CPX-351 in secondary/high-ri
📄 Read the full analysis here: https://t.co/T5IRxifU10

#Leukemia #HemOnc #Hematology #MedTwitter #RealWorldEvidence